PDF(Pubmed)
Abstract：
Sickle cell disease is the most common hemoglobinopathy among humans. As the condition promotes susceptibility to infections, chronic inflammation, and hypercoagulability disorders, several international agencies have included individuals with this disease in the COVID-19 risk group for severe outcomes. However, available information about the subject is not properly systematized yet. This review aimed to understand and summarize the scientific knowledge about the impact of SARS-CoV-2 infection in patients with sickle cell disease. Searches were performed in the Medline, PubMed, and Virtual Health Library databases based on descriptors chosen according to the Medical Subject Headings. We analyzed studies published between 2020 and October 2022, developed with qualitative, quantitative, or mixed methodology, and written in English, Spanish, or Portuguese. The search resulted in 90 articles organized into six categories. There is disagreement in the literature about how different aspects related to sickle cell disease, such as chronic inflammation status, hypercoagulability, hemolytic anemia, use of hydroxyurea, and access to medical care interference with the clinical course of COVID-19. These topics deserve further investigation. It is evident, however, that the infection may manifest in an atypical way and act as a trigger for the development of sickle cell-specific complications, such as acute chest syndrome and vaso-occlusive crises, conditions that are associated with great morbidity and mortality. Therefore, healthcare professionals must be aware of the different forms of presentation of COVID-19 among these individuals. Specific guidelines and therapeutic protocols, as well as public policies for sickle cell individuals, must be considered.
UNASSIGNED: This review (https://doi.org/10.17605/OSF.IO/NH4AS) and the review protocol (https://osf.io/3y649/) are registered in the Open Science Framework platform.
UNASSIGNED: This review (https://doi.org/10.17605/OSF.IO/NH4AS) and the review protocol (https://osf.io/3y649/) are registered in the Open Science Framework platform.
摘要：
镰状细胞病是人类中最常见的血红蛋白病。由于这种情况会促进对感染的易感性，慢性炎症，和高凝障碍，一些国际机构已将患有这种疾病的个体纳入COVID-19的严重结局风险组.然而,有关该主题的可用信息尚未适当系统化。本文旨在了解和总结SARS-CoV-2感染对镰状细胞病患者的影响的科学知识。搜索在Medline进行，PubMed,和基于根据医学主题词选择的描述符的虚拟健康库数据库。我们分析了2020年至2022年10月之间发表的研究，这些研究是用定性的、定量,或混合方法，用英语写的，西班牙语,或者葡萄牙语。搜索结果将90篇文章分为六类。文献中关于镰状细胞病的不同方面存在分歧，如慢性炎症状态，高凝状态,溶血性贫血,使用羟基脲，并获得对COVID-19临床病程的干扰。这些问题值得进一步研究。很明显,然而,感染可能以非典型的方式表现，并触发镰状细胞特异性并发症的发展，如急性胸部综合征和血管闭塞危象，与高发病率和死亡率相关的条件。因此,医疗保健专业人员必须意识到这些个体中COVID-19的不同表现形式。具体指南和治疗方案，以及针对镰状细胞个体的公共政策，必须考虑。
■此评论（https://doi.org/10.17605/OSF。IO/NH4AS）和审查协议（https://osf.io/3y649/）在开放科学框架平台中注册。
■此评论（https://doi.org/10.17605/OSF。IO/NH4AS）和审查协议（https://osf.io/3y649/）在开放科学框架平台中注册。
